Business Description
Viva Biotech Holdings
NAICS : 541714
SIC : 2834
ISIN : KYG9390W1015
Total Employee Number:
2,085Compare
Compare
Traded in other countries / regions
01873.Hong KongVBIZF.USAVB0.Germany IPO Date
2019-10-08Description
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.82 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.33 | |||||
Debt-to-EBITDA | 2.36 | |||||
Interest Coverage | 5.64 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 0.9 | |||||
Beneish M-Score | -2.13 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -16.2 | |||||
3-Year FCF Growth Rate | -13.4 | |||||
3-Year Book Growth Rate | -0.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.35 | |||||
9-Day RSI | 40.14 | |||||
14-Day RSI | 37.69 | |||||
3-1 Month Momentum % | -33.03 | |||||
6-1 Month Momentum % | -28.43 | |||||
12-1 Month Momentum % | -9.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.51 | |||||
Quick Ratio | 1.27 | |||||
Cash Ratio | 0.77 | |||||
Days Inventory | 103.94 | |||||
Days Sales Outstanding | 76.84 | |||||
Days Payable | 78.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.3 | |||||
Shareholder Yield % | 0.33 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 37.89 | |||||
Operating Margin % | 12.22 | |||||
Net Margin % | 12.7 | |||||
EBITDA Margin % | 32.75 | |||||
FCF Margin % | 6.34 | |||||
OCF Margin % | 13.42 | |||||
ROE % | 5.69 | |||||
ROA % | 3.15 | |||||
ROIC % | 3.05 | |||||
3-Year ROIIC % | 6.92 | |||||
ROC (Joel Greenblatt) % | 18.51 | |||||
ROCE % | 6.12 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.31 | |||||
PE Ratio without NRI | 14.74 | |||||
Price-to-Owner-Earnings | 28.72 | |||||
PS Ratio | 1.37 | |||||
PB Ratio | 0.54 | |||||
Price-to-Tangible-Book | 1.32 | |||||
Price-to-Free-Cash-Flow | 21.54 | |||||
Price-to-Operating-Cash-Flow | 10.28 | |||||
EV-to-EBIT | 6.7 | |||||
EV-to-EBITDA | 4.2 | |||||
EV-to-Revenue | 1.38 | |||||
EV-to-FCF | 21.7 | |||||
Price-to-GF-Value | 1.49 | |||||
Price-to-Projected-FCF | 1.08 | |||||
Price-to-Graham-Number | 0.99 | |||||
Earnings Yield (Greenblatt) % | 14.93 | |||||
FCF Yield % | 5.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viva Biotech Holdings Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 209.277 | ||
| EPS (TTM) (€) | 0.011 | ||
| Beta | 1.3649 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.46 | ||
| Volatility % | 88.98 | ||
| 14-Day RSI | 37.69 | ||
| 14-Day ATR (€) | 0.004292 | ||
| 20-Day SMA (€) | 0.12595 | ||
| 12-1 Month Momentum % | -9.32 | ||
| 52-Week Range (€) | 0.116 - 0.342 | ||
| Shares Outstanding (Mil) | 2,076.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viva Biotech Holdings Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viva Biotech Holdings Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2024 | 2025-06-26 10:00 | 0.17 (+0.00%) | ||
| Annual report for 2024 | 2025-04-25 | 0.17 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-09-26 | 0.07 (+0.00%) |
Show
Entries
Viva Biotech Holdings Frequently Asked Questions
What is Viva Biotech Holdings(FRA:VB0)'s stock price today?
The current price of FRA:VB0 is €0.12. The 52 week high of FRA:VB0 is €0.34 and 52 week low is €0.12.
When is next earnings date of Viva Biotech Holdings(FRA:VB0)?
The next earnings date of Viva Biotech Holdings(FRA:VB0) is .
Does Viva Biotech Holdings(FRA:VB0) pay dividends? If so, how much?
Viva Biotech Holdings(FRA:VB0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Viva Biotech Holdings
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers